Online inquiry

IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6350MR)

This product GTTS-WQ6350MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6350MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10097MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ5883MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ4609MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ10728MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-281
GTTS-WQ1686MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ12787MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ7689MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ1694MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA aDabi-Fab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW